Female viagra has been approved...only 27 years after the male version. The United States' Food and Drug Administration OK'd Sprout Pharmaceuticals' Addyi pill Tuesday in order to give women with sexual dysfunction some relief.

“Today’s approval provides women distressed by their low sexual desire with an approved treatment option,” said Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research. “The FDA strives to protect and advance the health of women, and we are committed to supporting the development of safe and effective treatments for female sexual dysfunction.”

Addyi (generic name: flibanserin) will be available in the U.S. starting Oct. 17 at a price on par with Viagra. The drug changes how brain cells react to chemicals associated with libido and will reportedly come with the strongest FDA warning available to underscore the risk of blood pressure drops and fainting when used with alcohol or other drugs.

According to The National Post, more than 1,300 Canadians were involved in the flibanserin trials. “It’s a significant problem for many, many women and we, at this point, don’t have anything that is available to help women in Canada,” said Dr. Jennifer Blake, chief executive officer of the Society of Obstetricians and Gynaecologists of Canada, in May.

Meanwhile, the FDA approved Viagra, Pfizer's impotence medication for men, way back in 1998 (it became available in Canada that same year). Sildenafil was patented in 1996 and approved only two years later, meanwhile flibanserin has been struggling for approval for five years.

"We've now got 24 drugs for men for either testosterone replacement or erectile dysfunction," Cindy Whitehead, Sprout's chief operating officer, said in 2013. "Yet there are zero drugs for the most common form of sexual dysfunction in women."

Well, now there is at least one.